<DOC>
	<DOCNO>NCT02688140</DOCNO>
	<brief_summary>Acute promyelocytic leukemia ( APL ) rare subtype acute myeloid leukemia ( AML ) characterize consistent clinical , morphologic , genetic feature . According FAB classification APL designate '' M3 leukemia '' assign WHO define type AML recurrent cytogenetic abnormality , `` acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) , ( PML/RARα ) variant '' . Despite dramatic progress achieve frontline therapy APL ATRA plus anthracycline-based regimen , relapse still occur approximately 20 % patient . Moreover , regimen associate significant toxicity due severe myelosuppression frequently associate life-threatening infection potentially serious late effect include development secondary MDS/AML . In recent randomized clinical trial low/intermediate-risk APL ( WBC ≤ 10 GPt/l APL0406 trial ) combination arsenic trioxide ( ATO ) ATRA show result well survival significantly low toxicity rate compare standard ATRA + idarubicin ( AIDA ) therapy . Inspired result trial investigator intend perform randomize study high-risk APL ( WBC diagnosis &gt; 10 GPt/l ) compare standard AIDA-based treatment ATO/ATRA combination include low-doses idarubicin induction . The investigator propose modify ATO/ATRA protocol addition two dos IDA ( 50 % compare standard AIDA induction ) induction anticipate need add anthracyclines control hyperleukocytosis achieve long-term disease control high-risk APL population . This follow 4 cycle ATO/ATRA consolidation therapy . As APL0406 study low/intermediate-risk patient investigator expect less severe hematologic toxicity treatment-related mortality result improved outcome patient experimental arm . Furthermore , start consolidation , patient ( contrast standard arm ) treat outpatient basis , also consider associate improved quality life . The study conduct European intergroup study .</brief_summary>
	<brief_title>Study Patients With Newly Diagnosed , High-risk Acute Promyelocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Informed consent Women men newly diagnose APL cytomorphology , confirm molecular analysis* Age ≥ 18 ≤ 65 year ECOG performance status 03 WBC diagnosis &gt; 10 GPt/l Serum total bilirubin ≤ 3.0 mg/dl ( ≤ 51 µmol/l ) Serum creatinine ≤ 3.0 mg/dl ( ≤ 260 µmol/l ) Women must fulfill least one follow criterion order eligible trial inclusion : Postmenopausal ( 12 month natural amenorrhea 6 month amenorrhea Serum FSH &gt; 40 U/ml ) Postoperative ( i.e . 6 week ) bilateral ovariectomy without hysterectomy Continuous correct application contraception method Pearl Index &lt; 1 % ( e.g . implant , depot , oral contraceptive , intrauterine device IUD ) Sexual abstinence Vasectomy sexual partner The confirmation diagnosis genetic level ( microspeckled PML nuclear distribution PGM3 monoclonal antibody and/or PML/RARa fusion RTPCR fluorescence situ hybridization ( FISH ) and/or demonstration ( 15 ; 17 ) karyotyping ) mandatory patient eligibility . However , order avoid delay treatment initiation , patient randomize basis morphologic diagnosis result genetic test available Patients eligible chemotherapy per discretion treat physician APL secondary previous radio chemotherapy nonAPL disease Other active malignancy time study entry ( exception : basalcell carcinoma ) Lack diagnostic confirmation genetic level Significant arrhythmia , ECG abnormality : Congenital long QT syndrome ; History presence significant ventricular atrial tachyarrhythmia ; Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 500msec screen ECG gender ( use QTcF formula detail protocol ) Right bundle branch block plus leave anterior hemiblock , bifascicular block Other cardiac contraindication intensive chemotherapy ( LVEF &lt; 50 % ) Uncontrolled , lifethreatening infection Severe non control pulmonary cardiac disease Severe hepatic renal dysfunction HIV and/or active hepatitis C infection Pregnant breastfeeding patient Allergy trial medication excipients study medication Substance abuse ; medical , psychological social condition may interfere patient participation study evaluation study result Use investigational drug time enrolment within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>APL</keyword>
	<keyword>acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>high-risk acute promyelocytic leukemia ( APL/AML M3 )</keyword>
	<keyword>acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>high-risk</keyword>
</DOC>